Company Profile

CIPLA LTD.

NSE : CIPLABSE : 500087ISIN CODE : INE059A01026Industry : Pharmaceuticals & DrugsHouse : Cipla
BSE476.25-2.25 (-0.47 % )
PREV CLOSE (Rs.) 478.50
OPEN PRICE (Rs.) 478.75
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 34245
TODAY'S LOW / HIGH (Rs.)474.70 483.05
52 WK LOW / HIGH (Rs.)465.5 678
NSE476.10 -2.2 (-0.46 % )
PREV CLOSE(Rs.) 478.30
OPEN PRICE (Rs.) 477.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 476.10 (41 )
VOLUME 1279325
TODAY'S LOW / HIGH(Rs.) 474.50 483.40
52 WK LOW / HIGH (Rs.)465 678.45

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.63
TTM EPS (Rs.) 27.20
P/E Ratio 17.51
Book Value (Rs.) 203.91
Face Value (Rs.) 2
MCap (Rs. in Mn) 383804.16
Price/Earning (TTM) 13.85
Price/Sales (TTM) 3.15
Price/Book (MRQ) 2.34
PAT Margin (%) 14.48
ROCE (%) 16.69
Incorporation Year : 1935

Management Info :

Y K Hamied - Chairman Umang Vohra - Managing Director

Registered Office :

Address : Cipla House,Peninsula Business Park,Ganpatrao Kadam Marg, Lower Parel,
Mumbai,
Maharashtra-400013

Phone : 022-24826000 / 022-24826951

Website : www.cipla.com

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg, MCX
NEWS More
13Aug08-13-2019$Cipla informs about conference call Cipla informs about conferen

Cipla has informed that it has enclosed a copy of the transcript of the Companys Q1 FY20 earnings conference call dated 7 August 2019. The transcript is also available on the Company's website i.e. www.cipla.com under the Investor Information section.

The above information is a part of company’s filings submitted to BSE.

Cipla has informed that it has enclosed a copy of the transcrip..
08Aug08-08-2019$Phoenix Mills, NBCC and Shriram Transport Finance to see some action today Phoenix Mills, NBCC and Shri

Phoenix Mills has entered into scheme of amalgamation with its subsidiary company -- Phoenix Hospitality Company (PHCPL). The Scheme was approved by the Board of Directors of both the companies at respective board meetings held earlier August 07, 2019 and will become effective from the appointed date of April 01, 2019 subject to receipt of approvals from National Company Law Tribunal at Mumbai, BSE, NSE, Securities and Exchange Board of India (SEBI), shareholders and other relevant regulatory authorities.

NBCC (India) has secured the total business of Rs 201.77 crore in the month of June and July, 2019.

Shriram Transport Finance Company has raised funds aggregating to Rs 10 crore through allotment of 100 Senior Secured Rated Listed principal protected Market Linked Redeemable Non-Convertible Debentures (NCDs) of face value of Rs 10,00,000 each on private placement basis.

Cupid has received an order worth Rs 4.70 crore from UNFPA. The order is for supply of male condoms to Mozambique.

Cipla has signed definitive agreement to acquire the minority stake of Eight Roads Investment Mauritius II in its subsidiary -- Cipla Health. The transaction is expected to be completed within a month.

Adani Ports and Special Economic Zone (APSEZ) has reported a rise of 36.14% in its net profit at Rs 489.23 crore for the quarter ended June 30, 2019 as compared to Rs 359.36 crore for the same quarter in the previous year. Total income of the company increased by 11.83% at Rs 1,714.91 crore for Q1FY20 as compared Rs 1,533.55 crore for the corresponding quarter previous year.

J Kumar Infraproject has received Letter of Acceptance (LoA) from National Highways Authority for construction of Dwarka Expressway from Road Under Bridge (RUB) near Sector 21, Dwarka to Delhi Haryana border(Km 5.300 to Km 9.500)- Package 2 in Delhi on EPC Mode amounting to Rs 1540 crore.

Phoenix Mills has entered into scheme of amalgamation with its..
07Aug08-07-2019$Cipla reports marginal rise in Q1 consolidated net profit Cipla reports marginal rise

Cipla has reported results for first quarter ended June 30, 2019.   

The company has reported 77.70% rise in its net profit at Rs 694 crore for the quarter under review as compared to Rs 390.55 crore for the same quarter in the previous year. Total income of the company increased by 7.41% at Rs 3,322.74 crore for Q1FY20 as compared Rs 3,093.64 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a marginal rise of 0.35% in its net profit at Rs 447.15 crore for the quarter under review as compared to Rs 445.61 crore for the same quarter in the previous year. However, total income of the company decreased by 1.02% at Rs 4,067.39 crore for Q1FY20 as compared Rs 4,109.10 crore for the corresponding quarter previous year.  

Cipla has reported results for first quarter ended June 30, 201..
07Aug08-07-2019$Cipla signs definitive agreement to acquire stake in subsidiary Cipla signs definitive agree

Cipla has signed definitive agreement to acquire the minority stake of Eight Roads Investment Mauritius II in its subsidiary -- Cipla Health. The transaction is expected to be completed within a month.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla has signed definitive agreement to acquire the minority s..
29Jul07-29-2019$Cipla seeks favourable policies for domestic pharmaceutical industry Cipla seeks favourable polic

Cipla has urged the government to increase fund allocation for the healthcare sector, improve ease of doing business and formulate policies that aid the domestic pharmaceutical industry.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla has urged the government to increase fund allocation for..
Financials More
Rs. in Millions
QTR Jun 19 ANNUAL 19
Net Profit694018884.1
Gross Profit 9783.3 24928.3
Operating Profit 11310.130795.2
Net Sales 32293.3123740.1
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Astrazeneca Pharma I (BSE)
 1708.40 (1.53%)
M.Cap ( in Cr)
4271.00
Everest Organics (BSE)
 172.65 (17.45%)
M.Cap ( in Cr)
138.12
Piramal Enterprises (BSE)
 1782.55 (0.90%)
M.Cap ( in Cr)
35445.39
Ajanta Pharma (BSE)
 996.45 (1.56%)
M.Cap ( in Cr)
8694.50
Samrat Pharmachem (BSE)
 73.20 (20.00%)
M.Cap ( in Cr)
22.62
Shareholding Pattern More
FI/BANKS/INSURANCE 4.12 %
PROMOTERS 36.7 %
NON-INSTITUTION 21.46 %
MUTUAL FUNDS/UTI 11.78 %
FII 0.67 %
GOVERNMENT 0 %
F & O Quotes